14 Perspectives of Aptamers for Medical Applications
451
65. Wang Q-L, Cui H-F, Song X, Fan S-F, Chen L-L, Li M-M, Li Z-Y (2018) A label-free and
lectin-based sandwich aptasensor for detection of carcinoembryonic antigen. Sens Actuat B
Chem 260:48–54
66. Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104(1):66–73
67. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a
monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331–1337. https://
doi.org/10.1172/jci110380
68. Moss EL, Hollingworth J, Reynolds TM (2005) The role of CA125 in clinical practice. J Clin
Pathol 58(3):308–312. https://doi.org/10.1136/jcp.2004.018077
69. Tripathi P, Kumar A, Sachan M, Gupta S, Nara S (2020) Aptamer-gold nanozyme based
competitive lateral flow assay for rapid detection of CA125 in human serum. Biosens
Bioelectron 165:112368. https://doi.org/10.1016/j.bios.2020.112368
70. Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A, Schwentner C
(2012) Thymidine kinase and cancer monitoring. Cancer Lett 316(1):6–10
71. Jagarlamudi KK, Shaw M (2018) Thymidine kinase 1 as a tumor biomarker: technical
advances offer new potential to an old biomarker. Biomark Med 12(9):1035–1048
72. Nazari M, Gargari SLM, Sahebghadam Lotfi A, Rassaee MJ, Taheri RA (2019) Aptamerbased sandwich assay for measurement of thymidine kinase 1 in serum of cancerous patients.
Biochemistry 58(18):2373–2383. https://doi.org/10.1021/acs.biochem.8b01284
73. Qian M, Li Q, Zhang M, Xu X, Shen Q, Chen H, Wang X, Liu T, Cheng Y (2020) Multidisciplinary therapy strategy of precision medicine in clinical practice. Clin Transl Med
10(1):116–124. https://doi.org/10.1002/ctm2.15
74. Dell’Italia LJ, Collawn JF, Ferrario CM (2018) Multifunctional role of chymase in acute and
chronic tissue injury and remodeling. Circ Res 122(2):319–336. https://doi.org/10.1161/cir
cresaha.117.310978
75. Atiakshin D, Buchwalow I, Tiemann M (2019) Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol 152(4):253–269. https://doi.org/10.1007/s00418-019-018
03-6
76. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, Dell’Italia LJ (2014)
An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci
126(7):461–469
77. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM (2011) Uptake and
metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS
ONE 6(1):e15759
78. Ahmad S, Wei C-C, Tallaj J, Dell’Italia LJ, Moniwa N, Varagic J, Ferrario CM (2013) Chymase
mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens
7(2):128–136
79. Butts B, Goeddel LA, George DJ, Steele C, Davies JE, Wei C-C, Varagic J, George JF,
Ferrario CM, Melby SJ (2017) Increased inflammation in pericardial fluid persists 48 hours
after cardiac surgery. Circulation 136(23):2284–2286
80. Jin D, Takai S, Nonaka Y, Yamazaki S, Fujiwara M, Nakamura Y (2019) A chymase inhibitory
RNA aptamer improves cardiac function and survival after myocardial infarction. Mol Ther
Nucl Acids 14:41–51. https://doi.org/10.1016/j.omtn.2018.11.001
81. Blann A (1993) von Willebrand factor and the endothelium in vascular disease. Br J Biomed
Sci 50(2):125–134
82. Spiel AO, Gilbert JC, Jilma B (2008) von Willebrand factor in cardiovascular disease: focus
on acute coronary syndromes. Circulation 117(11):1449–1459. https://doi.org/10.1161/circul
ationaha.107.722827
83. Vischer U (2006) von Willebrand factor, endothelial dysfunction, and cardiovascular disease.
J Thromb Haemost 4(6):1186–1193
84. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E (2005) Predictors of
the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies
and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26(5):440–446
451
65. Wang Q-L, Cui H-F, Song X, Fan S-F, Chen L-L, Li M-M, Li Z-Y (2018) A label-free and
lectin-based sandwich aptasensor for detection of carcinoembryonic antigen. Sens Actuat B
Chem 260:48–54
66. Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104(1):66–73
67. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a
monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331–1337. https://
doi.org/10.1172/jci110380
68. Moss EL, Hollingworth J, Reynolds TM (2005) The role of CA125 in clinical practice. J Clin
Pathol 58(3):308–312. https://doi.org/10.1136/jcp.2004.018077
69. Tripathi P, Kumar A, Sachan M, Gupta S, Nara S (2020) Aptamer-gold nanozyme based
competitive lateral flow assay for rapid detection of CA125 in human serum. Biosens
Bioelectron 165:112368. https://doi.org/10.1016/j.bios.2020.112368
70. Aufderklamm S, Todenhöfer T, Gakis G, Kruck S, Hennenlotter J, Stenzl A, Schwentner C
(2012) Thymidine kinase and cancer monitoring. Cancer Lett 316(1):6–10
71. Jagarlamudi KK, Shaw M (2018) Thymidine kinase 1 as a tumor biomarker: technical
advances offer new potential to an old biomarker. Biomark Med 12(9):1035–1048
72. Nazari M, Gargari SLM, Sahebghadam Lotfi A, Rassaee MJ, Taheri RA (2019) Aptamerbased sandwich assay for measurement of thymidine kinase 1 in serum of cancerous patients.
Biochemistry 58(18):2373–2383. https://doi.org/10.1021/acs.biochem.8b01284
73. Qian M, Li Q, Zhang M, Xu X, Shen Q, Chen H, Wang X, Liu T, Cheng Y (2020) Multidisciplinary therapy strategy of precision medicine in clinical practice. Clin Transl Med
10(1):116–124. https://doi.org/10.1002/ctm2.15
74. Dell’Italia LJ, Collawn JF, Ferrario CM (2018) Multifunctional role of chymase in acute and
chronic tissue injury and remodeling. Circ Res 122(2):319–336. https://doi.org/10.1161/cir
cresaha.117.310978
75. Atiakshin D, Buchwalow I, Tiemann M (2019) Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol 152(4):253–269. https://doi.org/10.1007/s00418-019-018
03-6
76. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, Dell’Italia LJ (2014)
An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci
126(7):461–469
77. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM (2011) Uptake and
metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS
ONE 6(1):e15759
78. Ahmad S, Wei C-C, Tallaj J, Dell’Italia LJ, Moniwa N, Varagic J, Ferrario CM (2013) Chymase
mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens
7(2):128–136
79. Butts B, Goeddel LA, George DJ, Steele C, Davies JE, Wei C-C, Varagic J, George JF,
Ferrario CM, Melby SJ (2017) Increased inflammation in pericardial fluid persists 48 hours
after cardiac surgery. Circulation 136(23):2284–2286
80. Jin D, Takai S, Nonaka Y, Yamazaki S, Fujiwara M, Nakamura Y (2019) A chymase inhibitory
RNA aptamer improves cardiac function and survival after myocardial infarction. Mol Ther
Nucl Acids 14:41–51. https://doi.org/10.1016/j.omtn.2018.11.001
81. Blann A (1993) von Willebrand factor and the endothelium in vascular disease. Br J Biomed
Sci 50(2):125–134
82. Spiel AO, Gilbert JC, Jilma B (2008) von Willebrand factor in cardiovascular disease: focus
on acute coronary syndromes. Circulation 117(11):1449–1459. https://doi.org/10.1161/circul
ationaha.107.722827
83. Vischer U (2006) von Willebrand factor, endothelial dysfunction, and cardiovascular disease.
J Thromb Haemost 4(6):1186–1193
84. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E (2005) Predictors of
the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies
and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26(5):440–446